"Israeli Researchers Probe How Cannabis Can Treat Endometriosis"

Israeli researchers have started pre-clinical studies to examine the impact of medical cannabis in the treatment of endometriosis, a medical problem that affects one in 10 women of childbearing age.

The research is led by Gynica, which is licensed by the Health Ministry to develop cannabis-based products for women, in cooperation with Lumir Lab, a cannabis research facility in the Biotechnology Park, Hadassah Ein Karem, Jerusalem.

Endometriosis affects some 176 million women worldwide. In affected women, uterine lining grows outside the uterus, in the fallopian tubes, ovaries and other areas of the abdominal cavity and in the pelvis. These women suffer from severe pain before and during menstruation, bleeding and pain during and after intercourse, dyspepsia and frequent or painful urination.

Anecdotal evidence has shown that women who smoke cannabis find relief from their pain, said Dr. Sari Sagiv, VP of research and development at Gynica. The researchers set out to find out what compounds or combination of compounds of cannabis can potentially address the problem.

"Beyond the CB1 & CB2... The Therapeutic Promise of TRPV1 & GPR55 Receptors"

If you’re familiar with cannabis science, you know about CB1 and CB2, the receptors located throughout the body that are triggered by cannabinoids like tetrahydrocannabinol (THC) and cannabidiol (CBD). 
It’s via these receptors that THC and CBD are able to bring about some of the therapeutic effects that cannabis is known for.

While CB1 and CB2 get the most attention—likely because we know the most about them—there are other receptors in the body that also respond to cannabinoids, like TRPV1 and GPR55. These receptors are influenced by THC and CBD, as well as anandamide and 2-arachidonoylglycerol (2-AG), endocannabinoids made by our bodies.

"Research on the TRPV1 and GPR55 receptors shows cannabinoids may hold promise in treating cancer and Dravet syndrome".

We’re beginning to gain a better understanding of TRPV1 and GPR55. Both hold much therapeutic promise, and CBD may be one of the ways to unlock this potential.

"A BRAVE YOUNG GIRL WITH A UNIQUE & INSPIRING PATH THROUGH CHILDHOOD LEUKEMIA"

"Some may say that cannabis does not “cure” cancer…

I am not saying the steroids and chemo didn’t help…
but all this right here shows something…
proof enough for me!

Some say cannabis is inappropriate for children…
We say cancer is inappropriate for children..."


This is the story of a little girl Mykayla that on July14th 2012, diagnosed with T-cell Acute Lymphoblastic Leukemia (ALL)
​
Leukemia is cancer of the blood and bone marrow.
Acute Lymphoblastic Leukemia (ALL) is a very rare and aggressive form of childhood leukemia, it accounts for 15-18% of childhood leukemia cases.

-In a healthy child, the bone marrow makes blood stem cells (immature cells) that become mature blood cells over time. A blood stem cell may become a myeloid stem cell or a lymphoid stem cell.

-In a child with ALL, too many stem cells become lymphoblasts, B lymphocytes, or T lymphocytes. The cells do not work like normal lymphocytes and are not able to fight infection very well. These cells are cancer leukemia cells.

"Cannabidiol Significantly Reduces Seizures in Patients with Severe Form of Epilepsy"

Researchers provide further evidence that the cannabis compound, CBD, is effective at reducing seizures in people with epilepsy. The new study reveals CBD significantly reduced seizures in people with Lennox-Gastaut syndrome. Previously, the researchers demonstrated CBD was effective at seizure control in Dravet syndrome.

Cannabidiol (CBD), a compound derived from the cannabis plant that does not produce a “high” and has been an increasing focus of medical research, was shown in a new large-scale, randomized, controlled trial to significantly reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.

"Cannabidiol could help deliver medications to the brain"

Cannabidiol (CBD), a non-psychoactive compound in cannabis, is being touted as beneficial for many health conditions, ranging from anxiety to epilepsy.

Although much more research is needed to verify these claims, scientists have now shown that CBD could have a different use as a "Trojan horse": helping slip medications across the blood-brain barrier (BBB).

The researchers report their results in the ACS journal Molecular Pharmaceutics.

The BBB consists of a layer of tightly linked cells that line capillaries in the brain, preventing substances from exiting the blood and entering the brain. However, the BBB does permit some molecules to pass, such as glucose and certain amino acids and neurotransmitters. For example, a class of neurotransmitters called endocannabinoids bind to proteins called cannabinoid receptors in the BBB, and the receptors help transport the molecules across the barrier and into the brain.

"Evidence for Therapeutic Properties of CBD/THC in Alzheimer's Disease"

Alzheimer's Disease (AD) is a debilitating neurodegenerative disease that is characterized by cognitive decline.

It is the most common form of dementia,accounting for over 60% of cases and affecting over 33 million people worldwide.


Unfortunately the current approved AD treatments only provide limited therapeutic benefits.

There are four approved drugs available, but unfortunately, all of them have been associated with adverse effects. Acetylcholinesterase inhibitors may cause nausea, vomiting, diarrhea and weight loss, while memantine is known to cause hallucinations, dizziness and fatigue.Furthermore, none of these treatments prevent or reverse the progression of the disease but rather they treat the disease symptoms with limited efficacy

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective, anti-inflammatory and antioxidant properties. It is investigated as a potential multifunctional treatment option for AD.

Here, we summarize the current status quo of effects of CBD in established pharmacological and transgenic animal models for AD.The phytocannabinoid cannabidiol (CBD) is a prime candidate for this new treatment strategy.

The in vivo therapeutic potential of CBD in AD has not been widely documented, however, there are a number of studies that have reported the effect of CBD in pharmacological models of AD. These studies have described anti-inflammatory and neuroprotective effects of CBD.

"A Pioneering Clinical Trial Investigate if Medical Cannabis Can Treat the Tics in Tourette Syndrome"?

A pioneering clinical trial investigating medicinal cannabis as a potential treatment for people living with Tourette syndrome will be conducted by Wesley Medical Research, with the cannabis supply facilitated by Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.

The trial is the first of its kind in Australia and will take place at Wesley Medical Research in Brisbane led by Chief Investigator and neuropsychiatrist Dr Philip Mosley. 

Participants will complete two periods of treatment with either a medicinal cannabis drug or a placebo, with both investigators and participants unaware of treatment status until the end of the trial.

Participants in the clinical trial at Wesley Medical Research will complete two six-week "crossover" periods of treatment with active drug or placebo, with both participants and investigators unaware of treatment status until the trial is complete.

"The Antiemetic effect of THC in patients receiving cancer chemotherapy"

Anecdotal accounts suggested that smoking marihuana decreases the nausea and vomiting associated with cancer chemotherapeutic agents.

In a study published in 16 Oct 1975 from 'The New England Journal of Medicine', oral THC (delta-9-tetrahydrocannabinol) was compared with placebo in a controlled, randomized, "double-blind" experiment. 


All patients were receiving chemotherapeutic drugs known to cause nausea and vomiting of central origin. Each patient was to serve as his own control to determine whether tetrahydrocannabinol had an antiemetic effect. Twenty-two patients entered the study, 20 of whom were evaluable. For all patients an antiemetic effect was observed in 14 of 20 tetrahydrocannabinol courses and in none of 22 placebo courses. 

For patients completing the study, response occurred in 12 of 15 courses of tetrahydrocannabinol and in none of 14 courses of placebo. No patient vomited while experiencing a subjective "high." 

Oral tetrahydrocannabinol has antiemetic properties and is significantly better than a placebo in reducing vomiting caused by chemotherapeutic agents.

"Just realize that this study is from 1975... but still we searching for evidence"

Source: https://www.nejm.org

"Can Medical Marijuana Help Transplant Patients"???

Certain conditions can result in the need for the patient to receive an organ transplant. When you need a transplant, you have to consider your eligibility, existing health issues, and recovery. Since some doctors consider medical marijuana a controversial topic, how does your patient status impact your experience? We can help you understand what to expect as a transplant patient who takes cannabis medicine.

Is Medical Marijuana Safe for Transplant Patients?

When you have an organ transplant, your doctor will give you immunosuppressants. As their name implies, these drugs suppress your immune system to increase your body’s chance of accepting the new organ. Your immune system attacks foreign objects, including organs that don’t belong to your body. If you have regular immune function, it will damage your new organ’s tissue. The immunosuppressants block its ability to attack the new organ so you can keep it in your body.

"Study Discover The Health Effects of Cannabis and Cannabinoids"

In March 2016, the Health and Medicine Division of the National Academies of Sciences, Engineering, and Medicine (the National Academies) was asked to convene a committee of experts to conduct a comprehensive review of the literature regarding the health effects of using cannabis and/or its constituents that had appeared since the publication of the 1999 IOM report Marijuana and Medicine. 

-The resulting Committee on the Health Effects of Marijuana consisted of 16 experts in the areas of marijuana, addiction, oncology, cardiology, neurodevelopment, respiratory disease, pediatric and adolescent health, immunology, toxicology, preclinical research, epidemiology, systematic review, and public health.


Given the large scientific literature on cannabis, the breadth of the statement of task, and the time constraints of the study, the committee developed an approach that resulted in giving primacy to recently published systematic reviews (since 2011) and high-quality primary research for 11 groups of health endpoints. For each health endpoint, systematic reviews were identified and assessed for quality using published criteria. Only fair- and good-quality reviews were considered by the committee.